AUREVIA CD
Advanced dual-phase cardiovascular wellness systems. A next-generation liquid-gel platform combining dedicated cyclodextrin and liposomal phases in one precisely separated daily format — combined only when used.
The foundation of the AUREVIA cyclodextrin platform.
View product →
Multi-pathway cardiovascular wellness, delivered through two precisely separated phases.
View product →
Practitioner circulation system for endothelial wellness, nitric oxide and fibrinolytic balance.
View product →AUREVIA DualPhase™ System.
Cyclodextrin intelligence. Liposomal precision.
A proposed two-phase formulation architecture that keeps cyclodextrins and liposomal phospholipids in separate storage environments until immediately before use.
Phase One — Cyclodextrin Matrix
- α-Cyclodextrin
- 2-Hydroxypropyl-β-cyclodextrin (HPβCD)
- Selected water-soluble ingredients
- Purified water
- Vegetable glycerin
- Controlled buffering system
- Natural flavour components where required
Phase Two — Liposomal Active Matrix
- Cholesterol-free sunflower phosphatidylcholine
- Selected lipid-soluble ingredients
- Purified phospholipids
- Natural mixed tocopherols
- Formula-specific antioxidants
- Appropriate viscosity and stability systems
Why the phases are separated
Cyclodextrins have internal hydrophobic cavities capable of participating in reversible inclusion interactions with compatible molecules. That does not mean every cavity remains permanently empty, or that every cavity becomes permanently occupied. The AUREVIA DualPhase™ System is designed to reduce prolonged pre-use contact between cyclodextrins and formulation phospholipids, preserve a measurable free or exchangeable cyclodextrin fraction, and let each chamber be manufactured and assessed independently.
One daily unit. Two dedicated chambers.
Dual-chamber liquid-gel sachet
- One Cyclodextrin Matrix chamber
- One Liposomal Active Matrix chamber
- Breakable or fold-activated internal seal
- Immediate combination before consumption
- 30 daily units per carton
Twin-pump system
- One cyclodextrin pump
- One liposomal-active pump
- Matched dispensing quantities
- Combined immediately before use
Final combined fill volume is pending confirmation by formulation and packaging engineers. All public product pages display [FINAL COMBINED FILL VOLUME PENDING] until published.
Before any finished CD product is marketed.
The DualPhase™ platform is assessed through a documented technical programme.
Cyclodextrin characterisation
Total α-CD and HPβCD content, free and exchangeable fractions, complexed fraction, recovery after chamber combination and after simulated digestion, retained inclusion capacity, interactions with phospholipids, flavour systems and packaging materials.
Liposomal characterisation
Vesicle particle size and distribution, PDI, zeta potential, encapsulation efficiency where applicable, phospholipid oxidation, active recovery, leakage over time, physical separation, sedimentation, aggregation and temperature sensitivity.
Combined-product testing
pH, viscosity, appearance, aroma, taste, mixing uniformity, dose delivery, chamber evacuation, active recovery, cyclodextrin availability and liposome behaviour under simulated gastric and intestinal conditions.
General quality programme
Identity, purity, strength, composition, microbiology, heavy metals, pesticide and residual solvent screening where relevant, oxidation markers, active assay, packaging integrity, fill-weight variation, seal integrity, accelerated and real-time stability, shipping stability and shelf-life confirmation.
Follow the science behind the DualPhase™ platform.
Methodology, evidence framework and product dossiers are published by Aurevia Evidence Sciences.